Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

LONDON, February 10, 2012 /PRNewswire/ --

-- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer --

-- Thomas Christély resigns as a Director of the Company --

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, announces today the promotion of Tony Sedgwick PhD, FRCPath to the role of Chief Executive Officer from Chief Business Officer with immediate effect and the departure of Thomas Christély who has resigned as a Director of the Company for personal reasons but will ensure a smooth transition.

Dr Anthony David Sedgwick (aged 56) joined Silence in September 2011 to lead a new business development team and has been instrumental since then in helping shape the Company's future strategy and in discussions with partners, investors and other stakeholders.  Tony has extensive experience from European life science companies including more than fifteen years at Roche.  Prior to joining Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS.  He was also previously CEO of two successfully acquired companies, Daniolabs Ltd. and Cambridge Biotechnology Ltd.

Commenting on the announcement Jerry Randall, Chairman of Silence Therapeutics, said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry.  He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the Company continues to gain momentum. On behalf of the Board I would like to thank
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... a timely and reliable way to obtain enough raw ... the tissue they need to build. In a new ... viscosity, and other mechanical properties of adult stem cells ... whether they will turn into bone, cartilage, or fat. ... of extracting the needed cells from a larger and ...
(Date:5/21/2012)... Elsevier,s Computers & Graphics announces the upcoming ... which will incorporate the Collage Authoring Environment, a workflow ... of the 2011 Executable Paper Grand Challenge. The call ... Eurographics 2012 on May 13, during the 3DOR Workshop. ... to embed chunks of executable code and data into ...
(Date:5/21/2012)... International scientific and government experts held a ... use of Oxitec,s genetically modified Aedes aegypti ... Panama. The independent forum was co-organised by ... Institute for Health Studies and the University of Panama. ... institutes as well as the Pan American Health Organisation, ...
(Date:5/18/2012)...  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that ... CEO, will be presenting at the Seventh Annual ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title ... Offer Attractive Targets for Active and Passive Immunotherapy." ... at the Intercontinental Hotel in Boston from 10:15-11:30 ...
Breaking Biology Technology:Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3
... On January 7,2008, Signalife received a deficiency letter ... it advised that Signalife would need to,comply with ... listing under AMEX Rules 1003(a)(iii). This notification was,triggered ... less than,$50 million, which previously exempted Signalife from ...
... New Agent for CLL Patients Approved by the FDA ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that the U.S. Food ... Injection for the,treatment of patients with chronic lymphocytic leukemia ... American Cancer Society,estimates that more than 15,000 new cases ...
... study setup and launch..., WAYLAND, Mass., March ... clinical trials software, announces the,launch of its Trident ... unique parameter driven + custom pluggable design,leaps ahead ... a new era,of needed scalability, productivity, and ease-of-use ...
Other Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
(Date:5/21/2012)... University of Singapore,s (NUS) Department of Biological Sciences and ... a compound that is undergoing preclinical trials as a ... and stop them from growing into a tumour. This ... the first time a research group has provided evidence ... , Building on the new findings, the NUS team ...
(Date:5/21/2012)... teams of Australian and US scientists has found there ... Antarctic Bottom Water found off the coast of Antarctica.,Comparing ... Southern Ocean marine science voyage to historical data dating ... much as a 60 per cent reduction in the ... that drives global ocean currents. , In an intensive ...
(Date:5/20/2012)... (HDAC) inhibitor panobinostat is able to target and ... study published in BioMed Central,s open access journal ... University Health Sciences Center have shown that panobinostat ... reduce tumor growth in mice. , Approximately 15% ... be triple negative. These aggressive tumours are missing ...
Breaking Biology News(10 mins):Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2San Diego State Offers Project Management Programs Beginning in January 61681 1San Diego State Offers Project Management Programs Beginning in January 61681 2Hobbits are a new human species according to the statistical analysis of fossils 10800 1Hobbits are a new human species according to the statistical analysis of fossils 10800 2Marrone Bio Innovations Named an IC20 Company 14914 1Marrone Bio Innovations Named an IC20 Company 14914 2
... Institute on Drug Abuse (NIDA), part of the National ... genes that might increase a person’s ability to abstain ... George Uhl at NIDA’s Intramural Research Program and a ... for Nicotine and Smoking Cessation Research at Duke University ...
... MIT have created an ocean model so realistic that the ... in population patterns that precisely mimic their real-world counterparts. , ... the vast diversity of the invisible forests living in our ... half the oxygen we breathe on Earth. And it does ...
... of millipede was recently discovered by a Northern Arizona ... researcher. , J. Judson Wynne, with the Department ... with the U.S. Geological Survey's Southwest Biological Center, and ... of Land Management (BLM), collected specimens leading to the ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2MIT's ocean model captures diversity of underwater forests 2MIT's ocean model captures diversity of underwater forests 3Discovery of new cave millipedes casts light on Arizona cave ecology 2Discovery of new cave millipedes casts light on Arizona cave ecology 3